BioCentury
ARTICLE | Company News

Genzyme exercises option on Dyax's DX-88

June 24, 2003 7:00 AM UTC

GENZ exercised its option under a 1998 deal to acquire a 50% interest in DYAX's DX-88 ( EPI-KAL2) recombinant kallikrein inhibitor protein to treat hereditary angioedema (HAE). The companies will shar...